On December 9, 2024, Talat Imran, the CEO of Rani Therapeutics Holdings Inc (RANI, Financial), purchased 10,296 shares of the company. Following this transaction, the insider now owns a total of 494,751 shares. The purchase was documented in a SEC Filing.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company focused on developing technologies to convert injectable biologics into oral pills. The company's innovative approach aims to improve the delivery and efficacy of biologic drugs.
The insider's recent acquisition is part of a broader trend observed over the past year, where the insider has purchased a total of 10,296 shares and sold none. This activity is reflected in the insider transaction history for Rani Therapeutics Holdings Inc, which shows 1 insider buy and 1 insider sell over the past year.
Shares of Rani Therapeutics Holdings Inc were trading at $1.94 each on the day of the purchase, resulting in a market cap of $64.291 million for the company.
For more information on the company's valuation, including its GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, please visit the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
